Distinct Associations of Age and CYP2D6 Genotype With Parent Venlafaxine Exposure and O‐Demethylation in Japanese Psychiatric Patients
Open Access
- 29 October 2026
- journal article
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (4)
Abstract
Background: Venlafaxine (VEN) is converted to O‐desmethylvenlafaxine (ODV) mainly through CYP2D6‐mediated O‐demethylation. However, age‐related clinical factors may also influence VEN exposure in routine practice. We examined whether age and CYP2D6 genotype show different associations with parent‐drug exposure and metabolic conversion. Methods: This retrospective therapeutic drug monitoring analysis included 78 Japanese psychiatric patients with available plasma VEN and ODV concentrations and CYP2D6 genotype data. Two prespecified outcomes were analyzed without body‐weight correction: VEN concentration divided by daily dose (VEN/dose) and the ODV/VEN ratio. CYP2D6*10 and *5 were coded as reduced‐ and no‐function alleles, respectively. Log‐transformed outcomes were analyzed using regression models including age and CYP2D6 reduced/no‐function allele count. Results: Nineteen patients (24.4%) were aged 65 years or older. Age was correlated with VEN/dose (Spearman rho = 0.295, p = 0.0086), and older patients had higher VEN/dose than younger patients (median, 0.522 vs. 0.192 [ng/mL]/[mg/day], p = 0.0127). In regression analysis, the incremental R 2 for age was numerically larger than that for CYP2D6 allele count for VEN/dose (incremental R 2 , 0.058 vs. 0.026). Conversely, the ODV/VEN ratio was strongly associated with CYP2D6 allele count (standardized beta = −0.391, p < 0.001; incremental R 2 = 0.145) but not with age. Age‐by‐genotype interactions were not significant for either outcome. Conclusions: Age appeared to be more closely related to dose‐corrected parent VEN exposure, whereas CYP2D6 genotype predominantly determined the ODV/VEN metabolic ratio. The relative contribution of age should be interpreted descriptively because no formal comparison of effect sizes was performed. Separating exposure and metabolic‐ratio outcomes may clarify how geriatric and pharmacogenetic factors contribute to VEN disposition.Keywords
This publication has 13 references indexed in Scilit:
- CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with DepressionClinical Pharmacology & Therapeutics, 2024
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor AntidepressantsClinical Pharmacology & Therapeutics, 2023
- CYP2D6*10 polymorphism and the enantioselective O‐desmethylation of S‐(+)‐ and R‐(‐)‐venlafaxine in Japanese psychiatric patientsBasic & Clinical Pharmacology & Toxicology, 2021
- Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With DepressionTherapeutic Drug Monitoring, 2020
- Significantly lower CYP2D6 metabolism measured as the O/N‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patientsBritish Journal of Clinical Pharmacology, 2018
- Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration RelationshipsBasic & Clinical Pharmacology & Toxicology, 2017
- Chirality in the New Generation of AntidepressantsTherapeutic Drug Monitoring, 2004
- Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteersBritish Journal of Clinical Pharmacology, 1999
- Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technologyPharmacogenetics, 1995
- Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.Molecular Pharmacology, 1994